Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
出版年份 2019 全文链接
标题
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 11, Pages 941-949
出版商
Informa UK Limited
发表日期
2019-10-08
DOI
10.1080/13543784.2019.1677606
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
- (2019) Qing-Feng Xiang et al. Artificial Cells Nanomedicine and Biotechnology
- First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
- (2019) Ying Fan et al. BMC CANCER
- Temporal trends in liver cancer mortality by educational attainment in the United States, 2000‐2015
- (2019) Jiemin Ma et al. CANCER
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
- (2019) Xiuqi Wu et al. MOLECULAR THERAPY
- Next-Generation Cancer Immunotherapy Targeting Glypican-3
- (2019) Yasuhiro Shimizu et al. Frontiers in Oncology
- Endothelial Cell-Derived TGF-β Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells
- (2019) Preety Rawal et al. Frontiers in Oncology
- Wnt/β-Catenin Signaling in Liver Cancers
- (2019) Wenhui Wang et al. Cancers
- FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
- (2019) Aroosha Raja et al. Cells
- A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
- (2018) Masafumi Ikeda et al. INVESTIGATIONAL NEW DRUGS
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
- (2018) Chi Ma et al. SCIENCE
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Infigratinib mediates vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma
- (2018) Hung Huynh et al. HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
- (2016) Ghassan K. Abou-Alfa et al. JOURNAL OF HEPATOLOGY
- Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor
- (2016) Xuemei Jiang et al. Frontiers in Immunology
- A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
- (2015) Hong Zhao et al. Oncotarget
- The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
- (2014) Friedhelm Bladt et al. Cancers
- Hepatocellular Carcinoma from an Immunologic Perspective
- (2013) T. F. Greten et al. CLINICAL CANCER RESEARCH
- A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
- (2013) Sharad Ghamande et al. INVESTIGATIONAL NEW DRUGS
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
- (2012) Y. Sawada et al. CLINICAL CANCER RESEARCH
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions
- (2011) Junmin Zhou et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
- (2009) Y. Hoshida et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started